Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer immunotherapies - Genmab/Immatics N.V.

Next Previous
X
Search
Drug Profile

Research programme: anticancer immunotherapies - Genmab/Immatics N.V.

Latest Information Update: 26 May 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; immatics biotechnologies GmbH
  • Developer Genmab; Immatics N.V.
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 25 May 2021 Preclinical trials in Cancer in Denmark, Germany (Parenteral) (Immatics pipeline, May 2021 )
  • 01 Jul 2020 Immatics N.V and Immatics Biotechnologies GmbH combined to form Immatics N.V.
  • 12 Jul 2018 Genmab and immatics enter into a research collaboration and exclusive license agreement to develop anticancer bi-specific immunotherapies

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top